FDA Investigator Patricia H Dlugosz

Patricia H Dlugosz has inspections in 10 countries as of 06 Oct 2023. Patricia H Dlugosz has collaborated with a combinined 3943 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
94
Last Inspection Date:
06 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, Israel, France, Canada, Ireland, Netherlands, Italy, Belgium, Norway, Denmark
Co-Investigator(s):
Adrian D Land, Alanna Lmussawwir Bias, Amanda L Baskin, Amina Bashir, Anastasia M Shields, Andrace Lde Yampert, Andre S Raw, Andrea D Swingle, Andrew H Paeng, Anissa M Vargas, Ann L Demarco, Anthony A Charity, Anthony Abel, Arnold Seo, PhD, Ashar P Parikh, Azza Talaat, Barbara J Rincon, Barbara Jwilimczyk Macri, Barbara L Rogolsky, Bei Y He, Benjamin J Smith, Bernard P Heidt, Bleta Vuniqi, Brandi N Mcgrady, Brett R Havranek, Brian D Garthwaite, Brian J Davis, Brian P Hendrickson, Bruce, Byungja E Marciante, Calvin K Cook, Carla A Norris, Carolyn E Barney, Cary Greene, Catherine J Laufmann, CDR Ileana Barreto Pettit, CDR Kimberly Y Martin, CDR Sean T Creighton, Charles I Ann, Charles L Zhou, Charles M Edwards, Charles M Spyr, Cheryl A Clausen, Christopher T Middendorf, Claire M Minden, Constantin Y Philopoulos, Corrine M Carter, Daniel J Gorski, Daniel J Lahar, Darren S Brown, Darren S Morgan, David A Paterson, David L Duncan, Dawn C Olenjack, Dawn M Braswell, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Dina A Tallman, Donald C Obenhuber, PhD, Donna K Speer, Douglas C Kovacs, Downer, Dr. Abhijit Raha, PhD, Dr. Roy A Blay, PhD, Emest F Bizjak, Emily J Orban, Erika V Butler, Erin D Mccaffery, Etty Feller, Farhana Khan, George J Flynn, Hamet Toure, PharmD MPH, Hans T Meyers, Helen B Ricalde, Heriberto Negron Rivera, Ifueko Osemwota, Jacqueline Mdiaz Albertini, James A Lane, James L Finn, Jamie L Dion, Janet L Bowen, Jean Blackston Hill, Jean Blackstone Hill, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Jennifer D Hollstrom, Jill J Tillman, Joanne M Schlossin, Jocelyn E Massey, Joey V Quitania, Joie A Navarrete, Jorge F Christian, Joris Vanloco, Jose E Melendez, DDC, Joseph A Piechocki, Joseph George, Joseph R Strelnik, Joy Rkozlowski Klena, Karen M Montgomery (KMM), Kathryn G Brown, Kathy E Craven, Kathy E Noe, Kelvin Cheung, Kenneth V Miller, Kent C Faul, Kevin Obrien, Kimberly A Dux, Kristina Mezin, Kristina Nastovski, L'oreal F Walker, Larry K Austin, Lauren Iacono Connors, PhD, Leigh Anne Myers, Leon L Law, Leonard H Lavi, Lewis K Antwi, Linda S Jozefiak, Lisa M Bellows, Logan T Williams, Luella J Rossi, Lynda L Lanning, Madushini Dharmasena, PhD, Marcellinus D Dordunoo, Marie Bbuen Bigornia, Marlon K Turner, Matt D Suedkamp, Matthew B Casale, Matthew J Gretkierewicz, Mei Chiung J Huang, Meisha R Sampson, Meisha Waters, Melina Rodriguez Upton, Mercy Oyugi, Michael A Charles, Michael E Maselli, Michael P Sheehan, Michael Shanks, MS, Michael Y Philopoulos, Michele Gottshall, Michele L Forster, PhD, Michele L Obert, Misty D Harvey, Montgomery Montgomery, Karen M, Mra Mcculloughj, Muna Algharibeh, Myra K Casey, Nailing Zhang, Nancy G Schmidt, Natalie A Mickelsen, DVM, Neal D Singletary, PhD, Neali H Lucas, Nicholas L Paulin, Nicole A Lloyd, Niketa Patel, Omotunde O Osunsanmi, Pankaj H Amin, Patricia A Birham, Patricia A Cochran, Patrick B Cummings, Patsy J Domingo, Paul A Bonneau, Paul L Figarole, Jr, Phillip Angart, PhD, Prabhu P Raju, Qiao Y Bobo, Qin Xu, Rafeeq A Habeeb, Ralph A Erickson, Rasha Bamieh, Raymond T Oji, Rebecca E Dombrowski, Rebecca Parrilla, Rebecca Rodriguez, Regina T Brown, Robert C Steyert, Robert D Tollefsen, Robert J Ham, Robert M Barbosa, Russell J Glapion, Saleem A Akhtar, Sandra A Boyd, Sandra A Hughes, Sangeeta M Khurana, PhD, Sanket N Patel, Santos E Camara, Sargum C Sood, Sidney B Priesmeyer, State Agency, Stephen D Brown, Steve Y Rhieu, PhD, Steven C Madzo, Susan F Laska, MS, Susan O Oladeji, Susan P Bruederle, Susanna E Ford, Analyst, Suyang Qin, Talmane J Fisher, Thomas J Arista, Thuy T Nguyen, LCDR, Timothy C Schell, Tina M Pawlowski, Tonya R Johnson, Torrance J Slayton, Tracey L Siebesma, Tracy K Li, Truong Xuan Nguyen (Andy), Vera M Anderson, Vlada Matusovsky, Wayne E Seifert, Wendy G Tan, PhD, William A Warnick, William D Tingley, Yangmin Ning, Yasamin Ameri, Yuesheng Ye, Yumi J Hiramine, Zachary L Miller

Patricia H Dlugosz's Documents

Publish Date Document Type Title
April, 2003 FDA 483 Priscilla Laboratories, Inc. - Form 483, 2003-04-25
August, 2000 FDA 483 Labcorp Drug Development Inc. - Form 483, 2000-08-30
October, 2000 EIR Jaques Meloche, M.D. - EIR, 2000-10-26
February, 2001 FDA 483 Response Eli Lilly and Company - Form 483R, 2001-03-08
June, 2000 FDA 483 Cohen, Gary W Md - Form 483, 2000-06-22
October, 2000 FDA 483 Response Marek Gawel, M.D. - Form 483R, 2000-10-24
January, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-01-25
January, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-01-24
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-24
November, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-11-14
June, 2000 FDA 483 Cohen, Gary W Md - Form 483, 2000-06-22
May, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-05-30
November, 2000 EIR Prystowsky, Eric N., Dr. - EIR, 2000-11-17
June, 2000 EIR Cohen, Gary W Md - EIR, 2000-06-22
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14
April, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-04-05
July, 2002 FDA 483 Paras Harshawat, M.D. - Form 483, 2002-07-12
August, 2000 EIR Evonik Corporation - EIR, 2000-08-11
October, 2000 FDA 483 Response Jaques Meloche, M.D. - Form 483R, 2000-12-29
January, 2003 EIR Covance Bioanalytical Services, LLC - EIR, 2003-01-03
August, 2000 FDA 483 Response Evonik Corporation - Form 483R, 2000-08-24
February, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-02-23
August, 2003 FDA 483 Scholnik, Aaron MD - Form 483, 2003-08-18
January, 2003 FDA 483 Covance Bioanalytical Services, LLC - Form 483, 2003-01-03
January, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-01-11
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-14
January, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-02-06
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-11
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-03-22
August, 2003 EIR Scholnik, Aaron MD - EIR, 2003-08-18
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-06-04
November, 2001 FDA 483 Response Eli Lilly and Company - Form 483R, 2001-12-03
May, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-05-30
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14
May, 2002 EIR Eli Lilly and Company - EIR, 2002-05-30
June, 2001 EIR BWXT Medical Ltd. - EIR, 2001-06-15
June, 2002 EIR Cook Incorporated - EIR, 2002-06-25
October, 2000 EIR Marek Gawel, M.D. - EIR, 2000-10-24
August, 2000 EIR Labcorp Drug Development Inc. - EIR, 2000-08-30
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-03-22
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-05-30

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more